Evotec, C4X Discovery in Strategic Research Pact

Evotec and C4X Discovery Holdings have entered a research collaboration to optimize Orexin-1 selective inhibitors using C4XD’s NMR technology. Evotec will apply its drug discovery platform with C4XD to further develop several series of Orexin-1 selective inhibitors with the goal of developing treatments for addictive disorders.
 
Activation of the orexin-1 receptor in the brain is associated with stress-related addictive disorders (e.g. alcohol, nicotine, cocaine and opiates), while the activation of the orexin-2 receptor is associated with biorhythms and wakefulness. Identification and development of selective compounds that inhibit the orexin-1 pathway should provide treatments for addiction avoiding the sedative effects associated with inhibition of orexin-2.
 
“We are delighted to work with C4XD on this strategic collaboration. C4XD has an exciting technology that can really revolutionize how rational drug design is conducted, particularly on targets like Orexin where the conformation of drug-like ligands is particular important to on-target potency. With Evotec’s complementary expertise in computational chemistry, medicinal chemistry and pharmacology we look forward to help drive C4XD’s objective to develop compounds to treat addictive disorders,” said Dr. Mario Polywka, chief operating officer of Evotec.
 
“Through this collaboration with Evotec, we expect our novel biological discoveries and medical insights will be effectively and efficiently progressed into a state-of-the-art drug discovery and development program. The collaboration is already demonstrating the benefit of an alliance in accelerating drug discovery projects,” said Piers Morgan, chief executive officer of C4XD.